Company Filing History:
Years Active: 2015-2019
Title: Ingo Röhl: A Pioneer in Oligonucleotide Detection and siRNA Delivery
Introduction
Ingo Röhl, an innovative inventor based in Memmelsdorf, Germany, has made significant contributions to the fields of molecular biology and biotechnology. With a portfolio comprising two patents, Röhl's work focuses on the detection of oligonucleotides and the development of peptide-based systems for RNA interference delivery. His inventions pave the way for advancements in genetic research and therapeutic applications.
Latest Patents
Ingo Röhl's latest patents showcase his expertise and commitment to innovation. The first patent, titled "Simultaneous detection of oligonucleotides, a kit and a use related thereto," presents a method for concurrently detecting at least two distinct oligonucleotides of equal length from a single biological sample. This method involves creating a hybridization mixture with fluorescently labeled detection molecules of varying surface charges, followed by anion exchange high-performance liquid chromatography (HPLC) for separation and quantitative fluorescence readout.
His second patent, "Peptide-based in vivo siRNA delivery system," focuses on the targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. This invention integrates co-targeted melittin delivery peptides that enhance the penetration of RNAi polynucleotides into cells, providing a physiological response through reversible modification.
Career Highlights
Throughout his career, Ingo Röhl has been associated with prominent companies such as Arrowhead Madison, Inc. and Axolabs GmbH. His experience in these organizations has bolstered his development of cutting-edge technologies in the field of biotechnology. By combining his expertise in molecular biology with practical application, Röhl contributes to the growth and improvement of gene-targeting techniques.
Collaborations
Ingo Röhl has collaborated with esteemed professionals in his field, including David B. Rozema and David L. Lewis. These partnerships have not only enhanced the quality of his inventions but have also fostered a culture of innovation and collaborative problem-solving in research.
Conclusion
Ingo Röhl exemplifies the essence of modern innovation within biotechnology, particularly through his patents focused on oligonucleotide detection and siRNA delivery. His work continues to impact research and therapeutic strategies, embodying the spirit of scientific advancement. With a clear vision for the future, Röhl is positioned to contribute further to the evolution of molecular technologies.